JF
AKRO

Jump Financial’s Akero Therapeutics AKRO Stock Holding History

Jump Financial’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,854
Closed -$441K – 1551
2024
Q4 		$441K Sell
15,854
-40,396
-72% -$1.22M 0.01% 1138
2024
Q3 		$1.61M Buy
56,250
+10,697
+23% +$279K 0.03% 600
2024
Q2 		$1.07M Sell
45,553
-61,722
-58% -$1.32M 0.02% 788
2024
Q1 		$2.71M Buy
+107,275
New +$2.58M 0.07% 325
2023
Q1 		– Sell
-30,149
Closed -$1.65M – 1541
2022
Q4 		$1.65M Buy
30,149
+19,853
+193% +$851K 0.09% 312
2022
Q3 		$350K Buy
+10,296
New +$158K 0.01% 1061

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jump Financial's AKRO Position: Q1 2025 in Review

Jump Financial sold out of Akero Therapeutics (AKRO) in Q1 2025, closing a stake of 15,854 shares — an estimated $441K sold.

Jump Financial first reported a position in AKRO in Q3 2022 and held it in 6 quarters. The position peaked at $2.71M in Q1 2024. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

  • Jump Financial reported no remaining Akero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Jump Financial sold 15,854 Akero Therapeutics shares in Q1 2025, an estimated $441K.
  • Jump Financial first reported a position in Akero Therapeutics in Q3 2022 and held it in 6 quarters.
  • Jump Financial's Akero Therapeutics position peaked at $2.71M in Q1 2024.
  • 240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on Jump Financial's 13F filing for Q1 2025, filed 14 May 2025.